Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 197, Issue 1, Pages 76-81Publisher
WILEY
DOI: 10.1111/bjh.17992
Keywords
acute leukaemia; diagnostic haematology; flow cytometry; minimal residual disease
Categories
Funding
- European Commission [LSHB-CT-2006-018708]
- Medical University of Silesia [PCN-1-050/K/0/K]
Ask authors/readers for more resources
The standardized EuroFlow protocol with CD19 as the primary B-cell marker allows for sensitive and reliable MRD assessment in BCP-ALL patients undergoing chemotherapy. An alternative gating strategy has been developed for analyzing MRD in patients treated with CD19-targeting therapies, showing high concordance with original MRD data despite variations. This indicates that overall MRD analysis remains accurate even with differences in CD19 expression.
The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19-positive, whereas this was 81% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available